Iridian Asset Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Iridian Asset Management’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-8,046	Closed	-$250K	–	110
2014 Q3	$250K	Sell	8,046 -520	-6%	-$14.1K	﹤0.01%	66
2014 Q2	$222K	Sell	8,566 -3,995	-32%	-$88.7K	﹤0.01%	86
2014 Q1	$294K	Sell	12,561 -4,819	-28%	-$105K	﹤0.01%	91
2013 Q4	$441K	Hold	17,380	–	–	0.01%	90
2013 Q3	$355K	Sell	17,380 -1,540	-8%	-$34.3K	﹤0.01%	106
2013 Q2	$397K	Buy	+18,920	New	+$338K	0.01%	69

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Iridian Asset Management's SGNT Position: Q4 2014 in Review

Iridian Asset Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2014, closing a stake of 8,046 shares — an estimated $250K sold.

Iridian Asset Management first reported a position in SGNT in Q2 2013 and held it in 6 quarters. The position peaked at $441K in Q4 2013. 131 funds tracked by Wall St. Rank hold SGNT as of Q4 2014.

Iridian Asset Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
Iridian Asset Management sold 8,046 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2014, an estimated $250K.
Iridian Asset Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 6 quarters.
Iridian Asset Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $441K in Q4 2013.
131 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2014.

Based on Iridian Asset Management's 13F filing for Q4 2014, filed 10 Feb 2015.